Short answer
Hologic (HOLX) filed an 8-K current report with the SEC on April 7, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.01 (Notice of Delisting), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). One CVR issued per Hologic share and certain equity awards outstanding immediately before merger effectiveness.
- This filing includes Item 3.01, an item that often signal trouble.
Hologic 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- One CVR issued per Hologic share and certain equity awards outstanding immediately before merger effectiveness
- CVR holders may receive contingent future value tied to specified merger-related conditions
- Equiniti Trust Company appointed rights agent under the CVR Agreement
- Complete CVR terms contained in Exhibit 10.1, which governs holders’ rights and payment conditions
Item 1.02 · Termination of a Material Definitive Agreement
- Merger closing triggered full repayment and termination of the amended credit facility, including liens, guarantees, and unused commitments
- $400 million of 4.625% 2028 Notes set for redemption at 100% plus accrued interest
- $950 million of 3.250% 2029 Notes set for redemption at 100% plus accrued interest
- Funds irrevocably deposited with trustees, reducing refinancing and execution risk for noteholders
- $1.35 billion total senior notes principal targeted for redemption, reshaping post-merger debt structure
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Acquisition completed; Hologic became a wholly owned subsidiary of Parent
- Common shareholders received $76.00 cash per share plus one contingent value right
- Parent funded the transaction through equity and debt financing
- Options with exercise prices below $79.00 received cash and/or CVRs; options at $79.00 or higher were cancelled without consideration
- RSU and PSU holders generally received $76.00 cash plus CVRs, subject to award-specific vesting and performance terms
Item 3.01 · Notice of Delisting
- Nasdaq trading suspended before April 7, 2026 following completion of the Merger
- Form 25 requested to delist all common shares and deregister them under Section 12(b)
- Company plans Form 15 filing to terminate remaining share registration under Section 12(g)
- SEC reporting obligations under Sections 13 and 15(d) expected to be suspended after Form 15 effectiveness
Item 3.03 · Material Modification to Rights of Security Holders
- Company common shares automatically cancelled at the merger’s Effective Time
- Former shareholders’ rights ended except entitlement to receive the Merger Consideration
- Shareholders no longer retain voting, dividend, or other equity rights after completion
Item 5.01 · Changes in Control of Registrant
- Control-change details incorporated from the filing’s Introductory Note and Items 2.01, 3.01, 3.03, 5.02 and 5.03
- Investor impact depends on those referenced sections, including governance, leadership and shareholder-rights changes
Item 5.02 · Departure/Election of Directors or Officers
- Merger completion triggered resignation of all nine pre-merger directors and board committees
- José (Joe) E. Almeida became the sole named incoming director
- Stephen P. MacMillan exited all company and subsidiary positions
- Almeida appointed Chief Executive Officer, marking post-merger leadership transition
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Charter adopted at merger effective time, replacing prior governing document
- Bylaws amended and restated entirely using Merger Sub’s pre-closing form
- Governance framework now reflects merger structure and surviving company identity
- Investors should review Exhibits 3.1 and 3.2 for voting, director, and shareholder-rights changes
Item 7.01 · Regulation FD Disclosure
- Merger officially closed on April 7, 2026, transitioning the transaction from announced to completed
- José (Joe) E. Almeida appointed Chief Executive Officer on the closing date
- Leadership change creates execution and integration priorities for investors
- Exhibit 99.1 contains the closing announcement and additional transaction details
Item EX-99.1 · Exhibit EX-99.1
- Blackstone and TPG completed Hologic’s acquisition, taking the company private and ending public-market access
- Stockholders receive $76 per share cash plus non-tradable CVR worth up to $3 per share
- CVR payments depend on Breast Health revenue goals in fiscal years 2026 and 2027, creating contingent value risk
- Joe Almeida became CEO, succeeding retired Stephen MacMillan after more than 12 years leading Hologic
- Hologic common stock ceased trading and will be delisted from Nasdaq
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Hologic 8-K filings
Get the next HOLX 8-K as it lands
Follow HOLX for push alerts, or ask the research agent what this filing means.